INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade
- Oops!Something went wrong.Please try again later.
- INMB
Shares of INmune Bio Inc. plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New Drug (IND) application to initiate its Phase 2 trial of its XPro Alzheimer's treatment on clinical hold. Also in the email, the FDA requested additional information around Chemistry Manufacturing and Controls (CMC) regarding the company's newly man